X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, NorthStar will be responsible for the production of 67Cu-SAR-bisPSMA drug product for Clarity’s Phase I/II and Phase III trials being developed in prostate cancer.
Lead Product(s): 67SAR-bisPSMA
Therapeutic Area: Oncology Product Name: 67SAR-bisPSMA
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Clarity Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 10, 2024
Details:
Under the collaboration, NorthStar will support by using its advanced technology and development and manufacturing expertise for the development of selected Curadh radiopharmaceutical targets for the diagnosis and treatment of solid tumor cancers.
Lead Product(s): Ac-225-based Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Recipient: CuradhMTR
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 03, 2024
Details:
Under the terms of the agreement, NorthStar will supply its high purity, n.c.a. Ac-225 to Curadh for use in its pioneering molecularly targeted radiation (MTR) programs for the treatment of common lethal tumors.
Lead Product(s): Actinium-225 Conjugated Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Curadh
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 29, 2023
Details:
SARTATE is highly targeted theranostic radiopharmaceutical. It is developed for diagnosing, staging and subsequently treating cancers that express somatostatin receptor 2. SARTATE product can be used with 64Cu for imaging (64Cu SARTATE) or 67Cu for therapy (67Cu SARTATE).
Lead Product(s): 67Cu-Sartate
Therapeutic Area: Oncology Product Name: 67Cu-Sartate
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Recipient: Clarity Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 28, 2023
Details:
Under the terms of the agreement, NorthStar will provide Bayer with its environmentally preferred, non-carrier added Ac-225. NorthStar’s Ac-225 will be used by Bayer for several of its radiopharmaceutical programs, including Actinium-225 conjugated Therapies.
Lead Product(s): Actinium-225 Conjugated Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Bayer AG
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 18, 2023
Details:
Under terms of the agreement, NorthStar will supply its high purity, non-carrier added Ac-225 to Nucleus. Nucleus will use NorthStar’s Ac-225 for their customers’ Actinium-225 conjugated therapy programs.
Lead Product(s): Actinium-225 Conjugated Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Nucleus RadioPharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 27, 2023
Details:
Under this agreement with Inhibrx, NorthStar will support the development of a prespecified number of Inhibrx’s novel biologic products by providing the Ac-225 supply for the Actinium-225 Conjugated Therapy and access to its integrated radiopharmaceutical CDMO services.
Lead Product(s): Actinium-225 Conjugated Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Inhibrx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 04, 2023
Details:
The agreement provide Aktis with a portfolio of suppliers that utilize varied techniques to produce high quality Actinium-225, and enhance the Company’s ability to ensure delivery of finished targeted radioconjugates to healthcare providers for administration to patients.
Lead Product(s): Actinium-225 Conjugated Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Recipient: Aktis Oncology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 23, 2022
Details:
Curie Therapeutics will be provided with priority access to NorthStar’s high purity non-carrier added n.c.a Ac-225, which will be used to advance its multimodal pipeline of precision radiopharmaceuticals to address broad unmet needs in treatment of patients with solid tumors.
Lead Product(s): n.c.a. Ac-225 Conjugated Therapeutic
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Curie Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 07, 2022
Details:
Under terms of the agreement, NorthStar will provide Convergent with its, high purity non-carrier-added Ac-225. Convergent will use NorthStar’s Ac-225 to radiolabel its lead asset, CONV01-α, a prostate-specific membrane antigen targeted monoclonal antibody.
Lead Product(s): 225Ac−Rosopatamab
Therapeutic Area: Oncology Product Name: CONV01-α
Highest Development Status: UndisclosedProduct Type: Large molecule
Recipient: Convergent Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 09, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
